Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer

Related Experiment Video

Updated: Oct 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Noriaki Sunaga1, Yosuke Miura1, Norimitsu Kasahara2

  • 1Department of Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi 371-8511, Gunma, Japan.

Cancers
|December 10, 2021
PubMed

Insights

Targeting KRAS G12C mutations in non-small-cell lung cancer (NSCLC) shows promise. This review covers KRAS mutations, targeted therapies, resistance mechanisms, and combination strategies for improved NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Precision Medicine

Background:

  • KRAS mutations are common drivers in non-small-cell lung cancer (NSCLC).
  • Targeting KRAS is crucial for precision medicine in NSCLC.
  • KRAS G12C inhibitors represent a significant advancement.

Purpose of the Study:

  • To review the role of KRAS mutations in NSCLC development.
  • To summarize preclinical and clinical evidence for targeting KRAS-mutated NSCLC.
  • To discuss resistance mechanisms and combination therapies for KRAS G12C inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of molecular biology advances in NSCLC.
  • Discussion of resistance mechanisms and therapeutic strategies.

Main Results:

  • KRAS mutations are key oncogenic drivers in NSCLC.
  • KRAS G12C inhibitors offer therapeutic potential.
  • Tumor heterogeneity necessitates combination therapies.

Conclusions:

  • Targeting KRAS G12C is a promising strategy for NSCLC.
  • Overcoming resistance through combination therapies is essential.
  • Further research into combination treatments is needed for diverse KRAS-mutated NSCLC.
Keywords:
combination therapycovalent KRAS G12C inhibitordrug resistancenon-small-cell lung cancerv-Ki-ras2 Kirsten rat sarcoma viral oncogene

More Related Videos

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

6.9K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K